Advertising


News

COVID-19 vaccine efficacy fades over time: Study


Jolyon Attwooll


25/08/2021 5:08:58 PM

Vaccine-induced immunity against infection appears to slowly reduce as months pass, but evidence around hospitalisation is less clear. What does this mean for boosters in Australia?

AstraZeneca and Pfizer vials.
The efficacy of AstraZeneca and Pfizer vaccines appears to reduce over time. (Image: AAP)

A pre-print study investigating how well COVID-19 vaccines protect against infection shows they are effective against Delta, but less so as time goes on.
 
The analysis, a collaboration led by researchers at the University of Oxford, assessed the rate of infection in randomly selected private households across the UK.
 
It showed that while Pfizer offers higher protection following a second dose compared to AstraZeneca – defined by measuring the viral burden detected via an RT-PCR diagnostic test – its protection fades faster.
 
The research also suggests that the Delta strain causes higher viral burdens in those infected post-vaccination than the previous Alpha variant.
 
However, while the results indicate that efficacy may drop substantially as time passes – in Pfizer’s case by as much as 22% for every 30 days after the second dose – the authors wrote that they do not suggest any conclusive requirement for follow-up booster injections.
 
‘Whilst protection against hospitalisation and death is maintained, “booster” vaccinations may not be needed, particularly since infection post vaccination may provide a natural antibody boost,’ the authors write.

‘However, declines in immunity against infection demonstrate this needs to be monitored closely.’
 
Peter Collignon, an infectious diseases professor at the Australian National University Medical School, believes the results reinforce the underlying assumption that the vaccines are effective.
 
‘[They] show the vaccines work; they also show you may get some waning of immunity,’ he told newsGP.
 
‘Every vaccine fades over time, that’s not a real surprise. To my mind, the main point of the vaccines is to stop you dying and to stop you getting seriously ill as judged by hospitalisation.’
 
Both vaccines reached roughly the same efficacy rates in protecting against infection from Delta after around 4–5 months, the study authors conclude.
 
Those with signs of previous COVID-19 infection showed the strongest resistance after being vaccinated, the analysis showed – a finding that could spur those who have previously had the virus to get vaccinated.
 
The need for boosters has been carefully scrutinised recently as more countries follow the lead of Israel, the first nation to begin administering a third injection to the wider population.
 
The US Centers for Disease Control and Prevention (CDC) also recently revealed plans for a booster program, although the announcement did not cite concrete evidence that waning immunity will result in people being more at risk of chronic illness.
 
‘The current protection against severe disease, hospitalisation, and death could diminish in the months ahead, especially among those who are at higher risk or were vaccinated during the earlier phases of the vaccination rollout,’ the CDC said.
 
Professor Collignon does not believe existing data shows conclusively that protection afforded by Australia’s vaccines declines significantly against severe disease – although he says this needs to be watched closely.
 
He is also concerned that booster programs in developed nations will divert vaccines from poorer countries that need them more.

‘The problem with boosters is that is another big supply of vaccine you need, and as WHO [the World Health Organization] points out, you’re giving a third shot in western countries when [some] haven’t even had a first shot,’ Professor Collignon said.
 
‘That’s an equity issue. Also, there is no convincing evidence – if your endpoint is preventing serious disease and death – that you actually need them.’
 
A report on the study in the medical journal Nature concludes that Pfizer is around 92% effective at stopping people from developing a high viral load 14 days after the second dose.
 
Nature reports the study as showing the vaccine’s efficacy declined to 90% after 30 days, 85% after 60 days and 78% after 90 days. AstraZeneca’s efficacy began at 69% a fortnight after the second dose, falling to 61% after 90 days, the journal reports.
 
There was some limited data on the use of the Moderna vaccine – due to be available in Australia from next month – but not enough to draw conclusions on its efficacy after two doses.
 
One of the researchers, Professor Sarah Walker, said the results are encouraging for patients who have been vaccinated with AstraZeneca and Pfizer. But she also said there was not enough data to indicate the exact infectious period for vaccinated people and believes the study reinforces the need for a cautious approach, even after vaccination.
 
‘Both of these vaccines, two doses are still doing really well against Delta,’ Professor Walker told Nature.
 
‘[But] most of our tests are monthly [so] we can’t really say very much at all about how long people are infectious for and particularly whether that’s different with Delta.
 
‘Anyone who thinks that if they get infected having been vaccinated, they can’t transmit — that isn’t likely to be true.’
 
Data included test results from 384,543 people aged 18–64 from 1 December 2020 to 16 May 2021, when the Alpha variant of concern was dominant in the UK, and results from 358,983 individuals from 17 May to 1 August 2021. The second period marked when Delta took over as the main strain in the UK.
 
But while the results seem to provide an accurate recent picture of how Delta has impacted immunity, Professor Collignon believes the true sign of whether hospitalisation rates prove boosters are genuinely required will not emerge until next year.
 
‘There is not really good evidence, even in Israel, where they have done this longest, that you’re really seeing a waning of that type of protection as times goes on,’ he said.
 
‘It may be, but the jury’s out.’
 
Log in below to join the conversation.



AstraZeneca COVID-19 immunity Pfizer vaccine boosters vaccine rollout


newsGP weekly poll As a GP, how concerned are you about the health impacts of climate change?
 
59%
 
8%
 
25%
 
6%
Related






newsGP weekly poll As a GP, how concerned are you about the health impacts of climate change?

Advertising

Advertising


Login to comment

Dr Samir Ibrahim Elias Massiha   25/08/2021 8:25:04 PM

Common sense


Dr Ian   26/08/2021 8:32:53 AM

The vulnerable will need boosters because once we have 80% vaccination more virus will be in the community and it will infect the vulnerable with more comorbidity and there will be deaths in the doubly vaccinated after if we do not give boosters .
The hope is for an antiviral tablet which if given very early or post exposure works in influenza for example .
We also have precision antibodies the Monoclonal Antibodies which can which if given early have 70% effectiveness in reducing hospitalisation in unvaccinated persons and in people without prior infection .
The question is when will general practices be allowed to treat respiratory infections again without being shut down for two weeks if a Covid 19 patient presents .
Medical surgeries will be have to be safer with good ventilation masks still and spacing but even fresh air needs to be filtered against insects and pollens thankfully the technology is here .


Dr Kanwel Hameed   26/08/2021 10:03:40 AM

i do agree


Dr Paul Vernon Jenkinson   26/08/2021 11:26:16 PM

‘Anyone who thinks that if they get infected having been vaccinated, they can’t transmit — that isn’t likely to be true.’
Isn't this what is happening in Israel where ,despite high vaccination rate ,delta is surging there in vaccinated people?
It seems our vaccine passports might "run out" fairly quickly.


Dr Peter James Strickland   29/08/2021 4:59:48 PM

There are two points here. 1. The elderly (like me) should have received a mRNA vaccine for longer term antibody cover in the first place.
2. it may well be that the immunity being measured by Oxford University is be misleading, i.e. after vaccination the levels drop, and at about 6 months AZ and Pfizer produced AB may be about the same percentage cover on present research, BUT on a further exposure to the Covid 19 virus a rapid and marked increase may well come into action with both types of vaccination, and no, or limited symptoms of disease, will actually occur. We will see, but everyone on present knowledge will need a mRNA vaccine booster rather than AZ vaccine to have good cover in the future.


Dr Elias Youssef Samaha   11/09/2021 7:21:28 AM

The vaccine passport idea is absurd from a scientific perspective

People who are vaccinated protect themselves and so the message with should send is that of in the interest of self preservation we should be vaccinated , people should be given accurate data on risks and benefits and make a personal decision

Travel passport was invented by politicians and travel industry and has no scientific basis.

The only utility I can think of, is to indirectly force those who are unvaccinated to get vaccinated and make their life as difficult as possible by excluding them from travelling, entering shopping centres etc

There is lots of evidence that the vaccinated still have good viral loads when infected to cause transmission

The idea people who are vaccinated can travel quarantine free is not the public message a responsible government should be sending. This allows potential international outbreaks and spread of new viral lineages which I have no doubt exist that are worse than delta


Dr Brendan Leslie   18/09/2021 8:56:06 AM

I find it concerning that the comments from fellow GPs above are based on their own thought bubbles and nothing more. Nobody has quoted any evidence for their opinions. This makes them no more valid than those from randoms on Twitter and it damages the reputation of our profession.

Please take a moment to read the Cochrane reviews on antivirals for influenza. They don’t work very well.

Please share with us some evidence that the elderly should have been prioritised for mRNA vaccines in Australia.